Prior to the acquisition, Cambrooke was a privately-held business led by investors Galen Partners and Seventure Partners
Cambrooke Therapeutics, Inc. (Cambrooke), an innovator in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announced it has been acquired by Ajinomoto Co. Inc. (Ajinomoto), a worldwide leader in amino acids, pharmaceuticals, high-quality seasonings, processed foods, beverages, and specialty chemicals, through its subsidiary Ajinomoto North America, Inc. Prior to the acquisition, Cambrooke was a privately-held business led by investors Galen Partners and Seventure Partners.
Cambrooke Therapeutic has been acquired by Ajinomoto Co. Inc., through its subsidiary Ajinomoto North America, Inc.